The National Institute for Health and Care Excellence (NICE) has recommended cabotegravir (Apretude, ViiV Healthcare), an injectable form of preexposure prophylaxis (PrEP), marking a major milestone in HIV prevention across England and Wales. The decision, outlined in NICE’s final draft guidance, follows the drug’s approval for NHS use in Scotland in February 2025…
Read More
